Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tears may replace spinal taps for MS diagnosis

NCT ID NCT02016222

Diagnosis Sponsor: Lille Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a tear sample can diagnose primary progressive multiple sclerosis (MS) as accurately as a spinal tap. Currently, doctors need to collect spinal fluid to confirm this type of MS, which is invasive and uncomfortable. Researchers will compare proteins in tears and spinal fluid from 80 adults with progressive MS to see if tears can serve as a reliable alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, non-invasive tear test to diagnose primary progressive multiple sclerosis, avoiding the need for a spinal tap.
What could go wrong
This is an early-stage study with only 80 participants, so results may not apply to everyone. The tear test might not be accurate enough to replace the standard spinal fluid analysis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Start date

Apr 2011

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or more * Progressive neurological deficit after 12 months * At least 9 T2 brain lesions of minimum 3 mm evidenced by MRI and/or four or more T2 lesions of minimum 3 mm with positive Visual Evoked Potential and/or positive spinal cord MRI (at least two focal T2 lesions) Exclusion Criteria: * Asiatic persons * recurrent forms of the disease * Persons wearing contact lenses * Ocular Infection * Corticoid treatment at least 30 days before sampling * immunosuppressive or immunomodulatory treatment 3 months before sampling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary progressive multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis disease Lacerations primary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary progressive multiple sclerosis

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Marseille

    Marseille, 13354, France

  • Centre hospitalier intercommunal

    Poissy, 78303, France

  • Centre hospitalier régional universitaire

    Clermont-Ferrand, 63003, France

  • Centre hospitalier régional universitaire

    Lille, 59037, France

  • Centre hospitalier régional universtaire

    Strasbourg, 67091, France

  • Centre hospitalier universitaire

    Caen, 14033, France

  • Centre hospitalier universitaire

    Dijon, 21079, France

  • Centre hospitalier universitaire

    Nancy, 54035, France

  • Centre hospitalier universitaire

    Nîmes, 30029, France

  • Centre hospitalier universitaire (CHU), Nice

    Nice, Alpes Maritimes, 06003, France

  • Centre hospitaliere universitaire

    Bordeaux, 33404, France

  • Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)

    Lille, Nord, 59000, France

  • Hospices civils de Lyon

    Lyon, 69229, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.